CARsgen Therapeutics Holdings (HKSE:02171) EV-to-EBIT : -2.57 (As of Jun. 05, 2024)

CARsgen Therapeutics Holdings EV-to-EBIT Chart

CARsgen Therapeutics Holdings Semi-Annual Data
	Dec19	Jun20	Dec20	Jun21	Dec21	Jun22	Dec22	Jun23	Dec23
EV-to-EBIT	Get a 7-Day Free Trial				-2.13	-	-6.32	-	-2.23

Competitive Comparison of CARsgen Therapeutics Holdings's EV-to-EBIT

For the Biotechnology subindustry, CARsgen Therapeutics Holdings's EV-to-EBIT, along with its competitors' market caps and EV-to-EBIT data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

CARsgen Therapeutics Holdings's EV-to-EBIT Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, CARsgen Therapeutics Holdings's EV-to-EBIT distribution charts can be found below:

* The bar in red indicates where CARsgen Therapeutics Holdings's EV-to-EBIT falls into.

CARsgen Therapeutics Holdings EV-to-EBIT Calculation

CARsgen Therapeutics Holdings's EV-to-EBIT for today is calculated as:

CARsgen Therapeutics Holdings's current Enterprise Value is HK$2,090.81 Mil.
For company reported semi-annually, GuruFocus uses latest annual data as the TTM data. CARsgen Therapeutics Holdings's EBIT for the trailing twelve months (TTM) ended in Dec. 2023 was HK$-812.38 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

CARsgen Therapeutics Holdings  (HKSE:02171) EV-to-EBIT Explanation

This is a more accurate valuation of companies' operation because it considers the debt and cash on its balance sheet, and non-operating items such as interest payment, tax, and one-time items are not included in the Operating Income.

Joel Greenblatt calls the inversion of this ratio Earnings Yield (Joel Greenblatt) %.

CARsgen Therapeutics Holdings's Earnings Yield (Joel Greenblatt) % for the quarter that ended in Dec. 2023 is calculated as:

CARsgen Therapeutics Holdings's Enterprise Value for the quarter that ended in Dec. 2023 was HK$1,811.65 Mil.
For company reported semi-annually, GuruFocus uses latest annual data as the TTM data. CARsgen Therapeutics Holdings's EBIT for the trailing twelve months (TTM) ended in Dec. 2023 was HK$-812.38 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

CARsgen Therapeutics Holdings EV-to-EBIT Related Terms

Thank you for viewing the detailed overview of CARsgen Therapeutics Holdings's EV-to-EBIT provided by GuruFocus.com. Please click on the following links to see related term pages.

CARsgen Therapeutics Holdings (HKSE:02171) Business Description